Published on
Apr 11, 2025
Human medicines European public assessment report (EPAR): Xermelo, telotristat ethyl, Date of authorisation: 17/09/2017, ...
The benefits of adding Xermelo to treatment have been shown in one main study involving 135 patients with carcinoid syndrome whose diarrhoea had not been fully controlled with somatostatin analogues alone. Xermelo was compared with placebo (a dummy …
Source:
European Medicines Agency
-
Pending
